|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
National Health Commission of the People's
Republic of China. Chinese guidelines for diagnosis and treatment
of breast cancer 2018 (English version). Chin J Cancer Res.
31:259–277. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948.
2010.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Prat A, Adamo B, Cheang MC, Anders CK,
Carey LA and Perou CM: Molecular characterization of basal-like and
non-basal-like triple-negative breast cancer. Oncologist.
18:123–133. 2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Blows FM, Driver KE, Schmidt MK, Broeks A,
van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO,
Blomqvist C, et al: Subtyping of breast cancer by
immunohistochemistry to investigate a relationship between subtype
and short and long term survival: A collaborative analysis of data
for 10,159 cases from 12 studies. PLoS Med.
7(e1000279)2010.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Perou CM and Børresen-Dale AL: Systems
biology and genomics of breast cancer. Cold Spring Harb Perspect
Biol. 3(a003293)2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clinical Cancer Res. 13:4429–4434. 2007.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Blick T, Widodo E, Hugo H, Waltham M,
Lenburg ME, Neve RM and Thompson EW: Epithelial mesenchymal
transition traits in human breast cancer cell lines. Clin Exp
Metastasis. 25:629–642. 2008.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Hay ED: An overview of
epithelio-mesenchymal transformation. Acta Anat (Basel). 154:8–20.
1995.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Scanlon CS, Van Tubergen EA, Inglehart RC
and D'Silva NJ: Biomarkers of epithelial-mesenchymal transition in
squamous cell carcinoma. J Dent Res. 92:114–121. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Turley EA, Veiseh M, Radisky DC and
Bissell MJ: Mechanisms of disease: Epithelial-mesenchymal
transition-does cellular plasticity fuel neoplastic progression?
Nat Clin Pract Oncol. 5:280–290. 2008.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Nose A, Nagafuchi A and Takeichi M:
Isolation of placental cadherin cDNA: Identification of a novel
gene family of cell-cell adhesion molecules. EMBO J. 6:3655–3661.
1987.PubMed/NCBI
|
|
13
|
Wijnhoven BPL, Dinjens WN and Pignatelli
M: E-cadherin-catenin cell-cell adhesion complex and human cancer.
Br J Surg. 87:992–1005. 2000.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Li K, He W, Lin N, Wang X and Fan QX:
N-cadherin knock-down decreases invasiveness of esophageal squamous
cell carcinoma in vitro. World J Gastroenterol. 15:697–704.
2009.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chang L and Goldman RD: Intermediate
filaments mediate cytoskeletal crosstalk. Nat Rev Mol Cell Biol.
5:601–613. 2004.PubMed/NCBI View
Article : Google Scholar
|
|
16
|
Hu L, Lau SH, Tzang CH, Wen JM, Wang W,
Xie D, Huang M, Wang Y, Wu MC, Huang JF, et al: Association of
Vimentin overexpression and hepatocellular carcinoma metastasis.
Oncogene. 23:298–302. 2004.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wei J, Xu G, Wu M, Zhang Y, Li Q, Liu P,
Zhu T, Song A, Zhao L, Han Z, et al: Overexpression of vimentin
contributes to prostate cancer invasion and metastasis via src
regulation. Anticancer Res. 28:327–334. 2008.PubMed/NCBI
|
|
18
|
Li D and Roberts R: Human genome and
diseases: WD-repeat proteins: Structure characteristics, biological
function, and their involvement in human diseases. Cell Mol Life
Sci CMLS. 58:2085–2097. 2001.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Beck R, Ravet M, Wieland FT and Cassel D:
The COPI system: Molecular mechanisms and function. FEBS Lett.
583:2701–2709. 2009.PubMed/NCBI View Article : Google Scholar
|
|
20
|
De Baere E, Speleman F, Van Roy N, Mortier
K, De Paepe A and Messiaen L: Assignment of the cellular
retinol-binding protein 2 gene (RBP2) to human chromosome band 3q23
by in situ hybridization. Cytogenet Cell Genet. 83:240–241.
1998.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Presley JF, Ward TH, Pfeifer AC, Siggia
ED, Phair RD and Lippincott-Schwartz J: Dissection of COPI and Arf1
dynamics in vivo and role in Golgi membrane transport. Nature.
417:187–193. 2002.PubMed/NCBI View
Article : Google Scholar
|
|
22
|
Lee MC, Miller EA, Goldberg J, Orci L and
Schekman R: Bi-directional protein transport between the ER and
Golgi. Annu Rev Cell Dev Biol. 20:87–123. 2004.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Mi Y, Yu M, Zhang L, Sun C, Wei B, Ding W,
Zhu Y, Tang J, Xia G and Zhu L: COPB2 is upregulated in prostate
cancer and regulates PC-3 cell proliferation, cell cycle, and
apoptosis. Arch Med Res. 47:411–418. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Li ZS, Liu CH, Liu Z, Zhu CL and Huang Q:
Downregulation of COPB2 by RNAi inhibits growth of human
cholangiocellular carcinoma cells. Eur Rev Med Pharmacol Sci.
22:985–992. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wang XL, Shi J, Niu Z, Wang J and Zhang W:
MiR-216a-3p regulates the proliferation, apoptosis, migration, and
invasion of lung cancer cells via targeting COPB2. Biosci
Biotechnol Biochem. 84:2014–2027. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Wang Y, Chai Z, Wang M, Jin Y, Yang A and
Li M: COPB2 suppresses cell proliferation and induces cell cycle
arrest in human colon cancer by regulating cell cycle-related
proteins. Exp Ther Med. 15:777–784. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
An C, Li H, Zhang X, Wang J, Qiang Y, Ye
X, Li Q, Guan Q and Zhou Y: Silencing of COPB2 inhibits the
proliferation of gastric cancer cells and induces apoptosis via
suppression of the RTK signaling pathway. Int J Oncol.
54:1195–1208. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Yu H, Yao J, Du M, Ye J, He X and Yin L:
CDKN3 promotes cell proliferation, invasion and migration by
activating the AKT signaling pathway in esophageal squamous cell
carcinoma. Oncol Lett. 19:542–548. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Tan MS, Chang SW, Cheah PL and Yap HJ:
Integrative machine learning analysis of multiple gene expression
profiles in cervical cancer. PeerJ. 6(e5285)2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Bhandari A, Zheng C, Sindan N, Sindan N,
Quan R, Xia E, Thapa Y, Tamang D, Wang O, Ye X and Huang D: COPB2
is up-regulated in breast cancer and plays a vital role in the
metastasis via N-cadherin and Vimentin. J Cell Mol Med.
23:5235–5245. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Thompson EW, Paik S, Brünner N, Sommers
CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME,
et al: Association of increased basement membrane invasiveness with
absence of estrogen receptor and expression of vimentin in human
breast cancer cell lines. J Cell Physiol. 150:534–544.
1992.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Xu Q, Chang H, Tian X, Lou C, Ma H and
Yang X: Hypoxia-induced MFAP5 promotes tumor migration and invasion
via AKT pathway in head and neck squamous cell carcinoma. J Cancer.
11:1596–1605. 2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Zhang YZ, Zheng YP and Zhu GM: MiR-203a-3p
targets PTEN to promote hepatocyte proliferation by regulating
PI3K/Akt pathway in BRL-3A cells. Biosci Biotechnol Biochem.
84:725–733. 2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Umemura S, Yoshida S, Ohta Y, Naito K,
Osamura RY and Tokuda Y: Increased phosphorylation of Akt in
triple-negative breast cancers. Cancer Sci. 98:1889–1892.
2007.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Shao Z, Ma X, Zhang Y, Sun Y, Lv W, He K,
Xia R, Wang P and Gao X: CPNE1 predicts poor prognosis and promotes
tumorigenesis and radioresistance via the AKT singling pathway in
triple-negative breast cancer. Mol Carcinog. 59:533–544.
2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Zhang Y, Zhao Z, Li S, Dong L, Li Y, Mao
Y, Liang Y, Tao Y and Ma J: Inhibition of miR-214 attenuates the
migration and invasion of triple-negative breast cancer cells. Mol
Med Rep. 19:4035–4042. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zhou Y, Wang X, Huang X, Li XD, Cheng K,
Yu H, Zhou YJ, Lv P and Jiang XB: High expression of COPB2 predicts
adverse outcomes: A potential therapeutic target for glioma. CNS
Neurosci Ther. 26:309–318. 2020.PubMed/NCBI View Article : Google Scholar
|
